top of page

Unveiled: How Covishield Became an Alarming Catalyst for Debate

Advocate Vishal Tiwari, who filed the PIL, called for the Centre to implement a vaccine damage payment system for citizens who are severely disabled as a result of the vaccination drive during COVID-19.
Title image for the article 'Unveiled: How Covishield Became an Alarming Catalyst for Debate' on The image shows a blurred background of an Indian architectural monument, overlayed with torn newspaper clippings about Covishield vaccine controversies and a prominently displayed Covishield vaccine vial.

Table Of Contents

Introduction: The Alliance of AstraZeneca and Serum Institute of India Amid Controversies.

Section 1: Covishield Vaccination Drive in India.

Section 2: Controversies Surrounding Covishield and AstraZeneca.

Section 3: Impact of Lawsuits.

Section 4: Political and Social Implications.

Section 5: Personal and Societal Concerns & Precautionary Measures.

Conclusion and Call to Action.


Introduction: The Alliance of AstraZeneca and Serum Institute of India Amid Controversies

Welcome to our deep dive into one of the most pivotal stories in public health and politics today. In collaboration with the Serum Institute of India (SII), AstraZeneca has been at the forefront of the global battle against COVID-19 with their vaccine, Covishield. This vaccine has played a vital role not only in India's ambitious vaccination drive, which has been celebrated worldwide, but also in reaching low and middle-income countries across the globe. However, the journey has not been without its controversies.

Recent lawsuits popping up across Europe, citing serious side effects like Thrombosis with Thrombocytopenia Syndrome (TTS), have cast a shadow over these achievements. Additionally, the timing of these admissions and lawsuits—coinciding with India's general elections—raises questions about potential fearmongering and its impact on public perception and political landscapes.

Intro section image for the article 'Unveiled: How Covishield Became an Alarming Catalyst for Debate' on, discussing AstraZeneca side effects like Thrombosis with Thrombocytopenia Syndrome (TTS). The image shows a Covishield vaccine vial held over a detailed illustration of a blood vessel with a clot and red blood cells, highlighting the potential side effect.

In this article, we will explore the intricate partnership between AstraZeneca and SII, dissect the layers of controversy surrounding Covishield, and discuss the broader implications of these events on public health policies and political narratives in India. From examining the legal battles to uncovering the stories of those affected, we aim to provide a comprehensive understanding of the situation.

Banner post questioning readers about Covishield vaccination exposure. Features text 'Have you or someone you know been administered the Covishield vaccination? Could you be at risk?' on a blue background alongside an image of a Covishield vaccine vial, syringe, and a depiction of the coronavirus, prompting reader engagement.

Section 1: Covishield Vaccination Drive in India

Celebrating the Success of Covishield’s Vaccination Drive in India

Section_1 subsection image for the article 'Unveiled: How Covishield Became an Alarming Catalyst for Debate' on, discussing 'Celebrating the Success of Covishield’s Vaccination Drive in India'. The image features a collage with timeline milestones, a map showing vaccination coverage, and images of vaccination efforts across India, highlighting key dates and statistics up to 4 April 2023.

India's response to the COVID-19 pandemic through its vaccination drive is nothing short of historic. Initiated on January 16, 2021, the drive aimed first at healthcare and frontline workers, marking the beginning of what would become the world's largest vaccination campaign. By January 2023, India had administered over 220.16 crore doses of the COVID-19 vaccine, with Covishield, produced by Pune's Serum Institute of India, accounting for nearly 88% of these doses.

The phased approach adopted by the government ensured that different age groups and populations across the vast nation received their vaccinations in a timely and organized manner. This massive endeavor led to more than 95.86% of the adult population receiving at least one dose of a COVID-19 vaccine, with substantial numbers fully vaccinated.

The global community has recognized this monumental effort as the "world's largest and most successful vaccination drive," a testament to India's robust healthcare infrastructure, the unwavering dedication of its healthcare workers, and the resilience of its people. Despite challenges such as initial vaccine hesitancy and logistical hurdles, India's proactive measures have significantly curbed the spread of the virus, showcasing an exemplary model of rapid health mobilization.

Current Status and Impact of Covishield Vaccinations in India

As we advance into 2024, the Covishield vaccination continues to play a crucial role in India's health defense. With over 174 crore doses administered to date, the vaccine remains a cornerstone of the national vaccination strategy. Despite AstraZeneca's recent admission regarding the rare but serious risk of Thrombosis with Thrombocytopenia Syndrome (TTS), medical experts reassure the public that the risk remains exceedingly low, emphasizing that the benefits of vaccination significantly outweigh these risks.

The public's trust in Covishield, while shaken by recent controversies, is supported by extensive data and positive outcomes witnessed over the years. Legal developments and ongoing court cases will undoubtedly influence perceptions, but the foundational goal remains clear— to protect the health and well-being of India's populace through scientifically validated measures.

Section 2: Controversies Surrounding Covishield and AstraZeneca

Sarah Moore, a partner at Hausfeld, remarked, 'This legal battle raises a fundamental question: ... should the state provide adequate compensation, or must the bereaved and injured battle for it in court against the vaccine producer?

Unpacking the Legal Battles: Covishield’s Side Effects and European Lawsuits

The Covishield vaccine, developed by AstraZeneca and manufactured in India by the Serum Institute of India, has been surrounded by controversies primarily due to rare but serious side effects. In a notable development, AstraZeneca acknowledged in legal documents submitted to the UK High Court the potential risk of Thrombosis with Thrombocytopenia Syndrome (TTS), a condition characterized by clotting at unusual sites and sometimes accompanied by hemorrhaging. This admission has sparked a significant public debate about the safety of the vaccine, particularly concerning its use in diverse populations.

Experts, however, have emphasized that TTS is extremely rare and primarily poses a risk only in the first few weeks following the initial vaccination dose. This is particularly relevant in the context of India, where the majority of the population has already received multiple doses, and time has elapsed since these vaccinations. The benefits of vaccination, they argue, significantly outweigh the risks, which are minor when compared to the potential consequences of COVID-19.

Detailed Analysis: Allegations and Evidence in Covishield Lawsuits

Recent years have seen a series of lawsuits against AstraZeneca, not just for medical issues like PPI medications but also for the COVID-19 vaccine’s delivery delays and side effects. The allegations are particularly severe with respect to the COVID-19 vaccine, where claimants have cited severe health impacts such as catastrophic injuries from blood clots. These legal actions range from individual claims to potential class actions, with claimants seeking justice for what they allege are vaccine-induced injuries under the Consumer Protection Act 1987.

Key cases include a landmark settlement regarding PPI medications and ongoing disputes over the timely delivery of vaccines to the European Union, highlighting a pattern of legal challenges that have marked AstraZeneca's recent history.

Evidence Presented in Covishield Lawsuits

Section_2 subsection image for the article 'Unveiled: How Covishield Became an Alarming Catalyst for Debate' on, detailing 'Evidence Presented in Covishield Lawsuits'. The image is an entity-relationship diagram depicting the relationship between Medical Evidence, Adverse Event Reports, Consumer Protection Act, Product Liability, Vaccine Damage Payment Scheme, and Class Action, illustrating how these elements support legal claims in Covishield litigation.

In the ongoing legal battles involving AstraZeneca's Covishield vaccine, several types of evidence are being leveraged to support the claims of those affected by adverse effects. Here is a detailed look at the evidence being presented:

Medical Evidence:

  • Condition: Claimants diagnosed with Vaccine-Induced Thrombotic Thrombocytopenia (TTS), a condition causing potentially fatal blood clotting.

  • Documentation: Medical records and expert testimonies establishing the diagnosis and its direct link to the vaccine.

Adverse Event Reports:

  • Regulatory Findings: The Medicines and Healthcare Products Regulatory Agency has acknowledged a possible connection between the vaccine (Vaxzevria) and rare blood clot disorders paired with low platelet counts.

  • Utilization: This acknowledgment is used as critical evidence in the legal proceedings.

Consumer Protection Act 1987:

  • Safety Expectations: Claimants must demonstrate that the vaccine was not as safe as could reasonably be expected by the public.

  • Supporting Data: Includes statistics on the incidence of TTS and other adverse effects, alongside any lack of warning from AstraZeneca.

Vaccine Damage Payment Scheme:

  • Compensation Claims: Claimants are seeking compensation under this government-run scheme for vaccine-related injuries.

  • Supporting Evidence: Medical records that document severe impairments directly attributed to the vaccine.

Product Liability:

  • Claims Basis: Allegations that the vaccine was defective and less safe than promised.

  • Evidence Type: Comprises medical records, testimonies from medical experts, and possibly internal documents from AstraZeneca detailing the vaccine's development and side effects.

Class Action:

  • Group Litigation: Involves multiple individuals who suffered severe injuries or lost relatives due to the vaccine.

  • Documentation: Includes comprehensive medical records and expert analyses, supported by internal documents from AstraZeneca.

This evidence forms the backbone of the legal challenges facing AstraZeneca, illustrating the complexity and seriousness of the allegations and the robust nature of the judicial processes involved.

Understanding Thrombosis with Thrombocytopenia Syndrome (TTS) Linked to Covishield

Section_2 subsection image for the article 'Unveiled: How Covishield Became an Alarming Catalyst for Debate' on, discussing 'Understanding Thrombosis with Thrombocytopenia Syndrome (TTS) Linked to Covishield'. The image features detailed illustrations of various TTS symptoms including severe headache, blurred vision, and chest pain, with corresponding labels, emphasizing the risks associated with the Covishield vaccine.

Thrombosis with Thrombocytopenia Syndrome (TTS) is an extremely rare condition associated with the Covishield vaccine. This syndrome combines blood clots with a decrease in platelet count, presenting through various symptoms that may appear a few days to weeks after vaccination. Here are the key symptoms to be aware of:

  • Severe, persistent headache: Lasts more than 48 hours post-vaccination or appears more than 48 hours after vaccination.

  • Blurred vision: Difficulty in seeing details or slight haziness in vision.

  • Difficulty speaking: Challenges in articulating words or forming coherent sentences.

  • Drowsiness: Increased levels of sleepiness or lethargy that are not typical.

  • Seizures or confusion: Episodes of uncontrolled electrical disturbances in the brain or disorientation.

  • Shortness of breath: Difficulty in breathing or feeling as if you can't get enough air.

  • Chest pain: Any form of discomfort or pain in the chest area.

  • Nausea or vomiting: Frequent upset stomach or vomiting.

  • Swelling in your legs: Noticeable increase in size or puffiness in the leg area.

  • Persistent stomach pain: Continuous or severe abdominal pain.

  • Tiny blood spots under the skin (petechiae): Small red or purple spots on the body, indicating minor hemorrhages, not near the site of injection.

  • Leg pain or swelling: Pain or increased size in the legs that is unusual or unexplained.

  • Back pain: Any new or unusual pain in the back that occurs post-vaccination.

It is critical to understand that these symptoms are very rare, and the overall incidence of TTS is extremely low. However, should you or someone you know experience any of these symptoms, particularly between 4 and 42 days after receiving the vaccine, it is crucial to seek immediate medical attention. Prompt recognition and treatment are essential for managing this condition effectively.

Section 3: Impact of Lawsuits

Section_3 subsection image for the article 'Unveiled: How Covishield Became an Alarming Catalyst for Debate' on, discussing 'How Covishield Lawsuits Impact Serum Institute of India’s Operations'. The image features a flowchart with nodes titled 'Legal Action Against SII', 'Public Perception and Vaccine Hesitancy', and 'Regulatory Scrutiny', connected in a sequence, set against a blurred background of a laboratory.

How Covishield Lawsuits Impact Serum Institute of India’s Operations

The legal challenges faced by AstraZeneca have indirectly impacted the Serum Institute of India (SII), which is involved in the production of the Covishield vaccine under license. The key effects include:

  • Legal Action Against SII: Several lawsuits have been filed against SII by families in India, claiming adverse effects from the Covishield vaccine. These include serious health issues attributed to the vaccine, escalating to legal proceedings.

  • Public Perception and Vaccine Hesitancy: The controversy and subsequent lawsuits may influence public perception negatively, potentially increasing vaccine hesitancy. This could affect the overall vaccination rates and public health efforts in India.

  • Regulatory Scrutiny: Increased legal scrutiny could lead to more stringent regulatory oversight of SII’s production practices and vaccine safety protocols.

These factors collectively contribute to the pressure on SII and may influence its operational and strategic decisions moving forward. The resolution of these lawsuits and their public perception will be crucial for SII's future operations.

Responses from AstraZeneca and SII to Vaccine Controversy

Section_3 subsection image for the article 'Unveiled: How Covishield Became an Alarming Catalyst for Debate' on, highlighting 'Responses from AstraZeneca and SII to Vaccine Controversy'. The diagram showcases AstraZeneca and SII's strategic interactions with the legal system and public, including acknowledgment of side effects, legal defenses, and future healthcare plans, set against a background of a legal office.

AstraZeneca’s Response:

  • Admission of Side Effects: AstraZeneca acknowledged the risk of TTS associated with its vaccine in a legal document, asserting that while rare, the vaccine could cause such side effects.

  • Legal Defense: In court, AstraZeneca has defended its vaccine, emphasizing the rarity of these side effects and contesting the basis of claims against them.

  • Future Plans: Despite setbacks in some legal battles, AstraZeneca is actively evaluating its next steps, particularly concerning how these outcomes could affect future healthcare innovations and patient access to drugs.

SII’s Response:

  • Legal Challenges: SII has faced significant legal challenges from individuals claiming adverse effects from Covishield. While they have not made extensive public statements regarding recent allegations, they have previously defended the safety of their vaccine vigorously.

  • Defensive Posture: In past instances, SII has announced intentions to seek damages against what it termed as "malicious" allegations, showcasing their proactive legal strategy in defending their vaccine’s reputation.

Both AstraZeneca and SII are navigating a complex legal landscape that affects not only their operations but also the global perception of vaccine safety. The outcomes of these legal battles are yet to be fully realized and could have far-reaching implications for both entities.

Section 4: Political and Social Implications

Section_4 subsection image for the article 'Unveiled: How Covishield Became an Alarming Catalyst for Debate' on, focusing on 'Political and Social Implications'. The collage features headlines and news excerpts from The Economic Times, The Indian Express, News18, and Onmanorama, discussing the controversy and political debates around Covishield during India's elections, highlighting comments from political leaders and changes to public health messages.

Examining the Timing of Covishield Lawsuits During India’s Elections

The timing of the lawsuits against AstraZeneca and the Serum Institute of India (SII) coinciding with India's election season raises significant questions about the potential motives and impact on voter perception. As political parties gear up for the elections, the controversy over Covishield’s side effects has become a heated topic of discussion:

  • Political Rhetoric: Politicians from various parties have leveraged the situation to criticize their opponents, with claims that the controversy could sway voter opinions against the ruling party.

  • Vaccine Certificates: The decision to remove PM Modi’s photo from vaccine certificates during this period, although officially due to election code conduct, has been viewed by some as a response to the vaccine controversy.

This backdrop sets a complex stage where public health issues are intertwined with political strategies, potentially influencing the electoral outcomes.

Political Implications of AstraZeneca Lawsuits in India

The AstraZeneca lawsuits have stirred a broad debate about the responsibility of pharmaceutical companies and the oversight of health authorities, reflecting on the political landscape:

  • Public Trust and Government Response: The government's handling of the vaccine rollout and subsequent issues could significantly influence public trust. How political leaders address these concerns might sway public opinion and voter behavior.

  • Legal and Policy Repercussions: The legal proceedings against AstraZeneca and the calls for stricter vaccine safety evaluations highlight the need for robust regulatory frameworks, which could become a critical election issue.

Addressing Fearmongering and Public Sentiment in India’s Vaccine Debate

Section_4 subsection image for the article 'Unveiled: How Covishield Became an Alarming Catalyst for Debate' on, focusing on 'Addressing Fearmongering and Public Sentiment in India’s Vaccine Debate'. The image displays a mindmap with nodes labeled 'Role of Media in Shaping Perception', 'Media and Information Flow', 'Need for Accurate and Timely Information', and more, set against a blurred background of a medical professional in a lab.

In a nation celebrated for its massive and swift vaccination drive, the recent lawsuits and AstraZeneca’s admission of rare side effects have ignited fears and speculation, leading to accusations of fearmongering:

  • Rational Discourse vs. Fearmongering: It is crucial to distinguish between legitimate safety concerns and unfounded fearmongering. The latter can undermine public health efforts and create unnecessary panic.

  • Media and Information Flow: The role of the media and the dissemination of information play pivotal roles in shaping public perception. Ensuring that the public receives accurate and timely information is essential to prevent misinformation and maintain trust in health initiatives.

Join the Conversation: Navigating Through Noise

In the midst of our in-depth exploration of the Covishield controversy during India's critical election phase, it's essential to discern the line between valid concern and orchestrated fear. The lawsuits and public debates not only shape our understanding of vaccine safety but also fuel narratives that might skew public sentiment.

Spotlight Discussion: "Fearmongering Against India: Discussing the Targeted Attacks"

We invite you to delve deeper into this critical issue by joining our focused discussion on our platform. This segment, titled "Fearmongering Against India: Discussing the Targeted Attacks," aims to uncover whether these concerns are a reflection of genuine safety issues or if there is an element of strategic manipulation aimed at discrediting India’s achievements.

"Title image from the article 'Fearmongering Against India: Discussing the Targeted Attacks' on, used as a mid-article CTA in 'Unveiled: How Covishield Became an Alarming Catalyst for Debate'. The image depicts a wooden puppet manipulated by strings inside a vintage TV displaying the words 'FAKE NEWS' and 'Fearmongering Against India Discussing the Targeted Attacks', symbolizing the control and misinformation spread through media."

Visit us at to share your views, read expert analyses, and contribute to a more informed dialogue. Is the timing of these controversies merely coincidental, or is there a deliberate effort to influence public opinion during an election season? Let's dissect these narratives together and strive for a well-informed community that stands strong against unwarranted fear.

Engage with us, and let’s ensure that our discussions are guided by facts, not fear.

Section 5: Personal and Societal Concerns & Precautionary Measures

Section_5 subsection image for the article 'Unveiled: How Covishield Became an Alarming Catalyst for Debate' on, discussing 'Heartbreak and Hope: NDTV’s Report on the Tragic Loss Linked to Covishield'. The image includes news headlines from NDTV and The Economic Times about a young woman's death attributed to Covishield, with comments from her grieving parents planning to sue AstraZeneca and Serum Institute of India.

Heartbreak and Hope: NDTV’s Report on the Tragic Loss Linked to Covishield (Source: NDTV)

NDTV has brought to light the heart-wrenching story of Venugopalan Govindan and Rachana Gangu, parents who tragically lost their daughters, aged 20 and 18, due to complications believed to be related to the Covishield vaccine. Their daughters succumbed to conditions post-vaccination in 2021, sparking a major controversy as AstraZeneca admitted in UK court documents that the vaccine could cause rare side effects like Thrombosis with Thrombocytopenia Syndrome (TTS). This case has led to a writ petition filed in the Supreme Court of India, demanding a thorough medical investigation and compensation, reflecting deep societal impacts and personal losses experienced by families.

Addressing the Spectrum of Experiences: My Family's Vaccination Journey

Section_5 subsection image for the article 'Unveiled: How Covishield Became an Alarming Catalyst for Debate' on, showcasing 'Anecdote of family and mine with proof of me and my wife's final vaccination certificate'. The image displays the COVID-19 vaccination certificates of two individuals, emphasizing their positive vaccination experience with Covishield, alongside a hopeful message about overcoming COVID-19 as a community.

While the stories of loss and suffering are profound and demand attention, it's essential to also consider the broader experiences of the population that has been vaccinated without severe adverse effects. My family and I have been vaccinated with Covishield for over two years now, and we've experienced no serious health impacts. By sharing our vaccination certificates, we aim to present a balanced view, acknowledging the vaccine's benefits alongside the potential risks, countering the narrative of fear that can be disproportionately amplified.

Community Voices: Public Concerns Over Covishield Vaccination

The public response to the Covishield vaccination has been varied:

  • AstraZeneca's Admission: The company's admission of rare but serious side effects has heightened public anxiety and led to a robust debate on vaccine safety.

  • Legal Challenges: The initiation of legal actions by affected families against SII underscores the community's demand for accountability and safety reassurances.

  • Vaccine Hesitancy: These developments have inevitably influenced vaccine hesitancy, impacting public health efforts against COVID-19.

Pre-Vaccination Evaluation: Expert Advice on Preparing for Covishield

Section_5 subsection image for the article 'Unveiled: How Covishield Became an Alarming Catalyst for Debate' on, exploring 'Pre-Vaccination Evaluation: Expert Advice on Preparing for Covishield'. The image is a timeline with stages including Initial Consultation, Vaccine Evaluation, and Post-Vaccination Preparedness, with steps like Review Medical History, Discuss Current Medications, Understand Contraindications, and Plan for Possible Reactions.

To navigate the complexities surrounding Covishield, potential recipients should consider the following steps before vaccination:

  1. Review Medical History: Discuss any personal or family history of health issues, especially those related to blood conditions or immune system responses.

  2. Discuss Current Medications: Inform healthcare providers about all medications being taken, particularly those that might interact with the vaccine.

  3. Understand Contraindications: Be aware of any conditions that might warrant postponement or avoidance of the vaccine.

  4. Plan for Possible Reactions: Know the signs of adverse reactions and ensure quick access to medical care if symptoms develop post-vaccination.

Conclusion and Call to Action

Towards Informed Decision-Making: The Importance of Reliable Vaccine Information

In the landscape of vaccine distribution and public health, it is crucial to make decisions based on reliable, scientifically validated information. The journey of the Covishield vaccine illustrates the dual narrative of significant achievements and formidable challenges. Understanding the frequency, scope, and impact of adverse effects is essential for informed decision-making, emphasizing the need for transparency and accountability from both pharmaceutical companies and health authorities.

As we strive to balance the undeniable benefits of widespread vaccination against its potential risks, our approach must be nuanced and well-informed, ensuring that public health benefits are maximized while minimizing harm.

Join the Discussion: Share Your Covishield Experience and Insights

We encourage you to share your personal experiences and insights regarding the Covishield vaccine. Whether you have experienced the vaccine directly or have been influenced by the surrounding discussions, your stories are valuable to our community's understanding.

Join the conversation on our platform,, to share your perspective or engage with the experiences of others. Your input is vital in fostering a comprehensive understanding of the vaccine's impact and the public's perception.

Rationality Over Fear

In times of widespread uncertainty and concern, it's imperative to remain rational and not succumb to fearmongering. The importance of staying informed and up-to-date with correct information cannot be overstated—it is indeed the call of the hour.

“Let’s commit to being rational and avoid spreading fear in our communities.”

How are we ensuring that fear does not override factual discourse in our discussions about public health and vaccines? Join us in promoting a culture of informed discussion and evidence-based understanding.



  1. Serum Institute of India obtains emergency use authorization for AstraZeneca's COVID-19 vaccine - AstraZeneca

  2. Serum Institute of India to produce 1 billion doses of Oxford-AstraZeneca COVID-19 vaccine - IndiaTVNews

  3. Relationship between AstraZeneca and Serum Institute of India - Bing Search

  4. Serum Institute of India Official Website

  5. COVISHIELD FAQs - Serum Institute Of India

  6. India’s Covid-19 vaccination drive, one year on | Recap

  7. India completes 2 years of COVID vaccination — the success story so far

  8. How India pulled off a vaccination success story despite obstacles

  9. 'True success story of Atmanirbharta': Serum Institute and Bharat Biotech hail 100 crore COVID-19 vaccination milestone

  10. Coronavirus vaccine: India begins world's biggest drive - BBC

  11. Covid vaccine: India becomes second country to cross two billion doses - BBC

  12. Covaxin: WHO approves India Covid vaccine for emergency use - BBC

  13. AstraZeneca's admission of Covishield risk may spark legal battles in India

  14. Fact Check: Are AstraZeneca's Covishield-vaccinated Indians susceptible to developing TTS?

  15. AstraZeneca admits its vaccine causes clotting: Why Covishield vaccine ...

  16. AstraZeneca admits rare side effect risk in Covishield vaccine, sparks ...

  17. ‘No Cause for Alarm’: Experts Explain Actual Reason Behind Blood ...

  18. $425 Million Settlement with AstraZeneca in PPI Litigation

  19. Nexium Lawsuit: 2024 Lawsuit Updates & Top Nexium Lawyers - Drugwatch

  20. Coronavirus: EU sues AstraZeneca over vaccine delivery delays - BBC

  21. Thrombosis with thrombocytopenia syndrome (TTS) | healthdirect

  22. Thrombosis with Thrombocytopenia Syndrome: An Overview - Healthline

  23. Thrombosis with thrombocytopenia syndrome: Causes and more - Medical News Today

  24. Serum Institute faces lawsuit over Covishield side-effects

  25. After Covishield vaccine side effects disclosed, grieving parents move to court

  26. AstraZeneca admits its Covid vaccine can cause rare side effect

  27. Serum Institute to sue man who said vaccine made him ill

  28. Lok Sabha Elections 2024 and Covishield Vaccine Controversies

  29. Covishield’s Impact on Election Season: An Analysis

  30. Read more about the impact of Covishield vaccine on the 2024 Lok Sabha elections and public opinions against BJP as discussed by Akhilesh Yadav

  31. Fearmongering Against India: Discussing the Targeted Attacks -

  32. Explore the legal and political implications of AstraZeneca’s admission of Covishield risks sparking debates and potential legal battles in India

  33. NDTV covers tragic vaccine-related deaths

  34. Insights on public and legal reactions to Covishield's side effects

  35. Expert advice on vaccine preparation and safety

10 views0 comments


Rated 0 out of 5 stars.
No ratings yet

Add a rating
  • Pinterest
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
© Copyright©
bottom of page